13.01.2025 01:47:24
|
Alnylam Pharma Anticipates Achieving Non-GAAP Profitability In 2025
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) anticipates delivering non-GAAP operating income profitability in 2025.
Alnylam announced full year 2025 combined net product revenue guidance for ONPATTRO, AMVUTTRA (PN & CM), GIVLAARI and OXLUMO of $2.050 billion to $2.250 billion, representing combined full year growth compared to 2024 of 31% at the mid-point of the guidance range.
Preliminary global net product revenues for ONPATTRO and AMVUTTRA for the fourth quarter were approximately $56 million and $287 million, respectively.
Preliminary global net product revenues for GIVLAARI and OXLUMO for the fourth quarter were approximately $65 million and $44 million, respectively.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alnylam Pharmaceuticals Inc.mehr Nachrichten
12.02.25 |
Ausblick: Alnylam Pharmaceuticals informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
30.10.24 |
Ausblick: Alnylam Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) |
Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Alnylam Pharmaceuticals Inc. | 231,60 | -0,69% |
|